Nearly all men with advanced prostate cancer will receive androgen deprivation therapy (ADT) as primary treatment. Fortunately, the majority of men treated with ADT will experience objective disease response; however, these men are also likely to experience the adverse effects of ADT, such as fatigue, sexual dysfunction, decreased bone mineral density, and increased risk of cardiovascular morbi...

Aim: New androgen signaling directed therapies (AR Tx), including abiraterone acetate plus prednisone (AA + P) and enzalutamide (E), prolong survival in patients (pts) with mCRPC. Used sequentially, response to E given after AA + P is of shorter duration and less frequent. Assessing the evolution of the disease to a more resistant phenotype following each treatment is necessary to develop more ...

Cytochrome P450 17α-hydroxylase/17,20-lyase (CYP17A1) is a validated treatment target for the treatment of metastatic castration-resistant prostate cancer (CRPC). Abiraterone acetate (AA) inhibits both 17α-hydroxylase (hydroxylase) and 17,20-lyase (lyase) reactions catalyzed by CYP17A1 and thus depletes androgen biosynthesis. However, coadministration of prednisone is required to suppress the m...

H-MRS 375 2-deoxyglucose 85 3,30-diindolylmethane (DIM) 1269 3D culture systems 2342 450K Infinium Methylation BeadChip 781 ABCC10 696 abiraterone 2248 abiraterone acetate 1249 ABO blood type 174 access to healthcare 577 acetylation 61, 568 acinar to ductal metaplasia 817 acrylamide 987 acute promyelocytic leukaemia 874 adenocarcinoma 1993 adjuvant chemotherapy 1004, 1275 adjuvant intraperitone...

Purpose: To develop and validate a simple, rapid, sensitive and specific ultraperformance liquid chromatography mass spectrometry method for the quantification of the angiotensin II receptor antagonist, telmisartan (TEL), in human plasma. Methods: After simple protein precipitation using acetonitrile and methanol, TEL and internal standard (IS) abiraterone were separated on Acquity UPLC BEH C18...

BACKGROUND The value of continuation of luteinizing hormone-releasing hormone (LHRH) therapy in castration-resistant prostate cancer (CRPC) remains controversial and clear evidence is lacking. Argumentation for cessation of LHRH therapy is the prolonged suppression of testosterone levels after the withdrawal of LHRH analogues and the fact that disease progression occurs despite castration level...

Although most patients with prostate cancer respond to initial androgen-deprivation therapy, progression to castration-resistant prostate cancer (CRPC) is almost inevitable. In 2004, the docetaxel/prednisone regimen was approved for the management of patients with metastatic CRPC, becoming the standard first-line therapy. Recent advances have also led to an unprecedented number of approved new ...

© Touch MEdical MEdia 2013 Abstract castration-resistant prostate cancer (cRPc) has a poor prognosis: current chemotherapeutic approaches ultimately result in resistance and are associated with survival rates of less than 2 years. however, the last decade has seen an expansion in the number of therapeutic options for cRPc and the regulatory approval of several agents, including the chemotherapy...

In the past 12 months, three novel therapeutics-sipuleucel-T, cabazitaxel, and abiraterone acetate-were granted Food and Drug Administration regulatory approval for the treatment of metastatic castration-resistant prostate cancer (CRPC) patients based on phase III studies that showed a survival advantage. Other agents, including the novel antiandrogen MDV3100, are at an advanced stage of clinic...